The Effect of Protein-enriched Diet on Body Composition and Appetite (ProteinRich)
Obesity is a major problem worldwide and current dietary interventions are not proving to be enough to cease the increase in levels of obesity and its detrimental side effects, such as nonalcoholic fatty liver disease (NAFLD).
Existing data suggests that adjustments in the macronutrient composition of the diet, more specifically the protein content, may have beneficial effects on body composition and an antiobesegenic effect on appetite. This may be important in terms of controlling body weight and reducing the amount of fatty tissue within our bodies and organs, and therefore preventing obesity and its health related side effects.
The investigators will perform a study to investigate whether a high protein low energy diet compared to a normal protein low energy diet, in overweight adults can modify appetite and aid loss of weight and fat mass. Subjects will receive either a high protein low energy diet (1.34g protein/kg body weight) or a normal protein low energy diet (0.8g protein/kg body weight) in the form of 2 meal replacements and one conventional meal per day with 2 snacks for 12 weeks.
HYPOTHESIS In overweight subjects with the metabolic syndrome, a 12 week dietary intervention with a high protein low energy diet will lead to a reduced appetite, body weight and fat mass, more specifically to a greater fall in levels of fat in the liver and pancreas than a low energy normal protein diet.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
London, Reino Unido, W12 0NN
- Imperial College London
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Overweight and obese people as classified by BMI 27-35kg/ m2 (inclusive)
- A Finnish Diabetes Risk Score (FINDRISC) >8 [22]
- Waist circumference measurement of ≥102cm in males or ≥88cm in females
- Assessed as appropriate for inclusion, based on a prestudy screening (see section 3.4)
- Willingness and ability to give written informed consent and willingness and ability to understand, to participate and to comply with the study requirements
Exclusion Criteria:
- Claustrophobia
- Pacemaker, metal implant, clips, implanted device, shrapnel or bullets, metal in eyes that precludes magnetic resonance imaging
- Treatment with any medication that might affect the study outcome (e.g., medication that is affecting appetite regulation and/or blood flow)
- Current pregnancy or breast feeding
- Delivery within the last year
- Bariatric surgery
- History of any disease with unknown outcome
- Significant intercurrent disease or history of clinically significant disease of any type, in particular liver, kidney, or heart disease, any form of diabetes mellitus or psychiatric illness (including Depression as defined by BDIII score above 28)
- History of cancer, excluding skin cancer
- History of severe or multiple allergies, severe adverse drug reaction or leucopenia
- Smokers
- Regular drinkers of more than three units of alcohol daily (1 unit = 300 ml beer, 1 glass wine, 1 measure spirit)
- Subjects who have had a fluctuation of body weight >5% in the 3 months prior to entering into the study
- History of, or current evidence of, abuse of alcohol or any drug substance, licit or illicit
- Regular intake of overthecounter (OTC) medication (other than the occasional paracetamol/aspirin)
- Poor compliers or subjects unlikely to attend
- Blood donation within the 12 week period before the initial study dose
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: High protein low calorie meal replacements
Meal replacements with added protein powder(1.34g
pro/kg).
|
The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight).
Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.
|
|
Comparador falso: Normal protein, low calorie meal replacement group
The control group will have standard meal replacements (0.8g protein/kg body weight).
|
The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight).
Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Lipid Content of the Liver (Intrahepatocellular Lipid)
Periodo de tiempo: Change from Baseline at 12 weeks
|
Changes in body weight and body composition, more specifically visceral, muscle, liver and pancreas fat content will be measured using magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS).
Individual's data will be compared at baseline and at 12 weeks of following the diet and also to that of the participants given normal protein low energy diets.
This data may therefore support our hypothesis that high protein intakes may help to aid weight loss and reduce fat mass and would therefore be a viable option in the treatment of obesity.
|
Change from Baseline at 12 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Appetite Regulation, Measured by VAS and Food Intake.
Periodo de tiempo: Baseline and 12 weeks
|
It has also been suggested that highprotein diets are more beneficial in the regulation of appetite.
We therefore aim to measure any changes in appetite whilst on a highprotein lowenergy diet compared to a normalprotein lowenergy diet.
Changes in appetite will be measured using validated questionnaires assessing subjects feeling of hunger, pleasantness and volume able to eat as well as fullness.
This data may support our hypothesis that highprotein intakes may alter appetite regulation and therefore be a useful in the treatment of obesity.
|
Baseline and 12 weeks
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Composite Appetite Score AUC (Area Under Curve)
Periodo de tiempo: Baseline and 12 weeks
|
A composite appetite score was calculated combing all four appetite measures to give a summary measure of appetite. Each appetite measure was assessed using validated 100 mm visual analogue scales (VAS) for hunger, fullness, desire to eat, and prospective food consumption (PFC) with the most positive and most negative sensations anchoring opposite ends of the line, from 'Not at all' or 'Nothing' to 'Extremely' or 'A large amount'. Participants were asked to mark the line at the point corresponding to their perceived appetite at that time. There is no score which is better or worse. Composite Appetite score (mm min) = [desire to eat + hunger + (100 - fullness) + prospective consumption]/4, as described by (Anderson et al, 2002). This reflects the four appetite related VAS (visual analogue scale) questions and was used as a summary measure of appetite. Area Under the Curve (AUC) was calculated for composite appetites score using the trapezoidal rule. AUC scores range from 0-9000mm*min |
Baseline and 12 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Gary Frost, Imperial College London
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 12/LO/0592
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .